Rev up Your Résumé: Determining Factors in the Race for an Academic Library Position

Like Indianapolis 500 drivers preparing for the race, LIS students today are gearing up for a job search in a tight market. We are examining how certain choices impact a graduate’s success in the job market. Our survey of recent graduates determines the extent to which program rankings, coursework, activities, and internships provide a competitive edge in the academic library job market

Factors that Increase the Probability of a Successful Academic Library Job Search

Finding a position in an academic library can be challenging for recent Library and Information Science (LIS) graduates. While LIS students are often encouraged to seek out experience, network, and improve upon their technology skills in hopes of better improving their odds in the jobmarket, little research exists to support this anecdotal advice. This study quantifies the academic and work experiences of recent LIS graduates in order to provide a better understanding of what factorsmost significantly influence the outcome of their academic library job searches. The survey results demonstrate that the job outlook is most positive for candidates who applied early, obtained academic library experience (preferably employment), participated in professional conferences, and gained familiarity with committee work

Analyzing the Academic Library Job Pool: What Recent LIS Graduates Are Bringing to the Table

LIS students today are gearing up for a job search in a tight market. We are examining how the activities and experiences they participate in during graduate school impact success in the job market. The results of our survey show the extent to which program rankings, coursework, activities, and internships provide a competitive edge in the job market. Come explore our results and learn what recent LIS graduates have to offer your library

Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised concerns regarding the safety of dabigatran and rivaroxaban, but apixaban has not been evaluated despite current labeling supporting its use in this population. The goal of this study was to determine patterns of apixaban use and its associated outcomes in dialysis-dependent patients with ESKD and AF. Methods: We performed a retrospective cohort study of Medicare beneficiaries included in the United States Renal Data System (October 2010 to December 2015). Eligible patients were those with ESKD and AF undergoing dialysis who initiated treatment with an oral anticoagulant. Because of the small number of dabigatran and rivaroxaban users, outcomes were only assessed in patients treated with apixaban or warfarin. Apixaban and warfarin patients were matched (1:3) based on prognostic score. Differences between groups in survival free of stroke or systemic embolism, major bleeding, gastrointestinal bleeding, intracranial bleeding, and death were assessed using Kaplan–Meier analyses. Hazard ratios (HRs) and 95% CIs were derived from Cox regression analyses. Results: The study population consisted of 25 523 patients (45.7% women; 68.2±11.9 years of age), including 2351 patients on apixaban and 23 172 patients on warfarin. An annual increase in apixaban prescriptions was observed after its marketing approval at the end of 2012, such that 26.6% of new anticoagulant prescriptions in 2015 were for apixaban. In matched cohorts, there was no difference in the risks of stroke/systemic embolism between apixaban and warfarin (HR, 0.88; 95% CI, 0.69–1.12; P=0.29), but apixaban was associated with a significantly lower risk of major bleeding (HR, 0.72; 95% CI, 0.59–0.87; P<0.001). In sensitivity analyses, standard-dose apixaban (5 mg twice a day; n=1034) was associated with significantly lower risks of stroke/systemic embolism and death as compared with either reduced-dose apixaban (2.5 mg twice a day; n=1317; HR, 0.61; 95% CI, 0.37–0.98; P=0.04 for stroke/systemic embolism; HR, 0.64; 95% CI, 0.45–0.92; P=0.01 for death) or warfarin (HR, 0.64; 95% CI, 0.42–0.97; P=0.04 for stroke/systemic embolism; HR, 0.63; 95% CI, 0.46–0.85; P=0.003 for death). Conclusions: Among patients with ESKD and AF on dialysis, apixaban use may be associated with a lower risk of major bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with reductions in thromboembolic and mortality risk